

LZK Polyclonal Antibody

Catalog # AP70793

Product Information

| | |
|--------------------------|------------------------|
| Application | WB, IHC-P, IF, ICC, E |
| Primary Accession | O43283 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 108296 |

Additional Information

| | |
|---------------------------|--|
| Gene ID | 9175 |
| Other Names | MAP3K13; LZK; Mitogen-activated protein kinase kinase kinase 13; Leucine zipper-bearing kinase; Mixed lineage kinase; MLK |
| Dilution | WB~~Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/20000. Not yet tested in other applications. IHC-P~~N/A IF~~1:50~200 ICC~~N/A E~~N/A |
| Format | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide. |
| Storage Conditions | -20°C |

Protein Information


| | |
|--------------------------|--|
| Name | MAP3K13 (HGNC:6852) |
| Function | Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB- containing complex that phosphorylates inhibitors of NF-kappa-B. |
| Cellular Location | Cytoplasm. Membrane; Peripheral membrane protein |
| Tissue Location | Expressed in the adult brain, liver, placenta and pancreas, with expression strongest in the pancreas |

Background

Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is

kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.

Images



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.